Contracts › 75A50126F61020
75A50126F61020: Two-Way Immunogenicity Testing on Existing Clinical Trial Sera to Immunogenicity Superiority of a New Vaccine Strain Versus the Prototype Strain
Awarded to Glaxosmithkline, Llc by Office of Assistant Secretary for Preparedness and Response.
$493Kobligated
$493Kpotential value
29 October 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50126F61020 |
|---|---|
| Vehicle | 75A50122D00002 |
| Awardee | Glaxosmithkline, Llc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | 6505 Drugs and Biologicals |
| Place of performance | NC |
| Period of performance | 13 March 2026 to 29 October 2026 |
| Potential end | 29 October 2026 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record